公开(公告)号：US10398784B2

公开(公告)日：2019-09-03

申请号：US15858142

申请日：2017-12-29

Applicant: NORTHWESTERN UNIVERSITY

Inventor： Chad A. Mirkin ,  Caroline H. Ko ,  David A. Giljohann ,  Janina Luciano ,  Samuel A. Jensen ,  Alexander Stegh

IPC: C07H21/04 ,  A61K47/69 ,  A61K49/18 ,  C12N15/113

Abstract: Polyvalent nanoconjugates address the critical challenges in therapeutic use. The single-entity, targeted therapeutic is able to cross the blood-brain barrier (BBB) and is thus effective in the treatment of central nervous system (CNS) disorders. Further, despite the tremendously high cellular uptake of nanoconjugates, they exhibit no toxicity in the cell types tested thus far. This property is critical for therapeutic agent delivery applications for reducing off-target effects.

公开(公告)号：US20180193484A1

公开(公告)日：2018-07-12

申请号：US15858142

申请日：2017-12-29

Applicant: NORTHWESTERN UNIVERSITY

Inventor： Chad A. Mirkin ,  Caroline H. Ko ,  David A. Giljohann ,  Janina Luciano ,  Samuel A. Jensen ,  Alexander Stegh

IPC: A61K47/69 ,  A61K49/18 ,  C12N15/113

CPC classification number: A61K47/6923 ,  A61K47/6929 ,  A61K49/1851 ,  C12N15/113 ,  C12N2310/14 ,  C12N2320/32 ,  C12N2320/35

Abstract: Polyvalent nanoconjugates address the critical challenges in therapeutic use. The single-entity, targeted therapeutic is able to cross the blood-brain barrier (BBB) and is thus effective in the treatment of central nervous system (CNS) disorders. Further, despite the tremendously high cellular uptake of nanoconjugates, they exhibit no toxicity in the cell types tested thus far. This property is critical for therapeutic agent delivery applications for reducing off-target effects.